Press Releases

Seapine Previews Latest Integrated ALM Solutions for Development Enterprises Wanting to Control Quality and Provides an Inside Look at New Agile Capabilities

CINCINNATI--(BUSINESS WIRE)-- Seapine Software, a leading global provider of quality-centric application lifecycle management (ALM) solutions, will display its integrated suite of scalable, feature-rich ALM tools at this year's Enterprise Software Development Conference in San Mateo, California. Visitors to booth 401 will get a firsthand look at Seapine's upcoming 2010.1 product releases, designed to help enterprises control and enforce quality across the software development lifecycle.

Seapine's TestTrack 2010.1 product releases support an enterprise's transition to Agile and enable development teams to:

    --  Manage backlogs and releases
    --  Perform sprint planning and tracking
    --  Conduct user acceptance tests and define doneness criteria
    --  Support multiple products, projects, and distributed teams
    --  Generate burn-down, velocity, task board, time tracking, and other
        project-critical charts

"Seapine's ALM tools are cross-platform and built on flexible architectures using open standards to support today's popular development methodologies and best practices," says Paula Rome, TestTrack product manager, Seapine Software. "Our new product features give enterprises the flexibility to manage traditional development processes in parallel with Agile efforts. ESDC attendees will see that our ALM tools are the best solution for enterprises with complex development projects, seeking to deliver the highest quality software on time, on budget, and to a customer's specification."

Seapine's integrated suite of ALM solutions creates an underlying quality management system that runs throughout the requirements, design, development, and testing phases. Seapine will demonstrate how its tools work together to streamline communications, improve traceability, automate processes, and provide real-time visibility into development activities. "Seapine's development tools deliver enterprise ALM without the enterprise complexity," adds Rome. "We leverage an enterprise's existing infrastructure investment with ALM solutions that are easy to deploy and manage."

To learn more about Seapine's quality-centric ALM solutions, visit www.seapine.com/products.html.

About Seapine Software

With over 8,500 customers worldwide, Seapine Software, Inc. is the leading provider of quality-centric application lifecycle management solutions. Headquartered in Cincinnati, Ohio, with offices in Europe and Asia-Pacific, Seapine's development tools help organizations of all sizes streamline communication, improve traceability, achieve compliance, and deliver quality products. Seapine's products support best practices, integrate into all popular development environments, and run on Microsoft Windows(R), Apple Macintosh(R), Linux(R), and Sun Solaris(R) platforms.

    Source: Seapine Software, Inc.

HALIFAX, NOVA SCOTIA--(Marketwire - Feb. 10, 2010) - RBC Royal Bank today announced two new executive appointments for the New Brunswick and PEI markets.

Based out of Fredericton, Stephen Slauenwhite is the new Regional Vice President for its operations in Western New Brunswick which includes a team of over 200 staff who work out of 13 branches serving the bank's 102,000 customers in the area.

Stephen has an MBA from Saint Mary's University, 23 years in the financial services industry, and a career that encompasses personal, small business, and commercial banking, as well as operations. Prior to this appointment he was RBC's Vice President of Commercial Banking in Nova Scotia.

As Regional Vice President for Eastern New Brunswick & PEI, Lisette will be responsible for the bank's 99,000 customers who are served by more than 200 financial services professionals in 12 branches.

Fluently bilingual, with a Bachelor of Commerce from Universite de Moncton, 16 years in the financial services industry, and a career that has included client facing positions, sales management, and branch management, Lisette brings a solid background of experience and expertise to her new role. She will be based out of Moncton. Prior to this appointment Lisette was Manager of RBC's Mortgage Specialist team in Western and Northern NB.

With the largest team of financial planners in Atlantic Canada, RBC is also one of the region's largest corporate donors, having given $1.2 Million to a range of charitable organizations throughout New Brunswick and PEI last year.

Clients wishing to make an appointment for a financial review, to contribute to an RRSP or open a Tax Free Savings Account can call their branch or Royal Direct at 1-888-ROYAL-11 (769-2511).

FOR FURTHER INFORMATION PLEASE CONTACT:
        Royal Bank of Canada
        Lori Smith
        Manager, Public Affairs, Atlantic Canada
        902-421-8121

Source: RBC Royal Bank

BEIJING & SEOUL, South Korea--(BUSINESS WIRE)-- Shenogen Pharma Group and Chemizon, a division of Optomagic Co. Ltd. (KOSDAQ: 0101070) today announced a drug discovery collaboration agreement to create small molecule therapeutics targeting modulators of the ER-alpha 36 receptor.

"We are very pleased to enter into this collaboration with Chemizon whose experienced management team has a track record of success in creating promising drug candidates," said Dr. Jin Li, President of Shenogen Pharma Group. "This collaboration underscores our commitment towards creating orally administered, small molecule modulators of the non-classical Estrogen Receptor pathway that target indications including metastatic breast cancer and osteoporosis."

Chemizon will be responsible for a spectrum of activities for an integrated drug development program including lead optimization, assay development, ADME, DMPK, Computational chemistry, and animal pharmacology. Financial details of the transaction were not disclosed. "We are delighted that Shenogen, a world leader in the field of non-classical estrogen receptor signaling, chose Chemizon as their partner," said Dr. Anthony D. Piscopio, Chief Executive Officer, of Chemizon. "We expect the synergy resulting from this partnership will result in novel breakthrough therapies that will ultimately benefit patients afflicted with life threatening diseases."

About Shenogen: Shenogen is a privately held drug development venture that develops novel therapeutics and companion diagnostic kits that are targeted at a novel membrane associated estrogen receptor, the ER-alpha 36. Shenogen leverages the ER-alpha 36 technology platform and proprietary biology assays, as well as lead compounds derived from traditional Chinese medicine to find drugs targeted at cancer stem cells. The Company is led by an exceptional team of US trained returnees with strong industry experience. Shenogen effectively adopts a virtual pharma strategy by collaborating closely with many US and China-based research and development partners. Shenogen has a pipeline of small molecule and antibody therapeutics, its lead compound for breast cancer has entered clinical stage.

About Chemizon: Chemizon is a Life Sciences company that is focused on the discovery and development of targeted therapies to treat patients afflicted with cancer, inflammatory and metabolic diseases. Our collaborative programs, which are designed to regulate clinically relevant target proteins, are aimed at large, growing multi-billion dollar world-wide markets. We have assembled, through in-house platforms and strategic partnerships, a fully integrated discovery capability from target identification through proof of concept clinical trials. We utilize a business model that blends service, collaboration, and partnered IP generation, to balance risk and create sustainability, ultimately enhancing our shareholders return on investment. For additional information, please visit us at www.chemizon.com.

    Source: Chemizon

LONDON--(BUSINESS WIRE)--

Re: PERMANENT MASTER ISSUER PLC

    USD 489460000

    MATURING: 15-Jul-2042

    ISIN: XS0484703789

PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD

04-Feb-2010 TO 15-Apr-2010 HAS BEEN FIXED AT 1.393950 PCT

DAY BASIS: ACTUAL/360

INTEREST PAYABLE VALUE 15-Apr-2010 WILL AMOUNT TO:

USD 1326660.94 PER USD 489460000 DENOMINATION

    Source: Permanent Master Iss